menu
    • menu
    [{"orgOrder":0,"company":"Hope Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"HMI-115","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hope Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"HMI-115","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"","sponsorNew":"Hope Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Hope Medicine

    Menu

    Hope Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hope Medicine

                            China arrow
                            Pittcon 2025
                            Not Confirmed

                            Hope Medicine

                            China arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HMI-115

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hope Medicine Reports Positive Phase 2 Results for Endometriosis Treatment

                            Details : HMI-115 is an innovative antibody targeting the prolactin receptor. It is currently in Phase 2 clinical development for the treatment of moderate to severe pain associated with endometriosis in women.

                            Product Name : HMI-115

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 23, 2024

                            Lead Product(s) : HMI-115

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hope Medicine

                            China arrow
                            Pittcon 2025
                            Not Confirmed

                            Hope Medicine

                            China arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HMI-115

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Outcome from Phase Ib Study in Australia Treating Androgenic Alopecia Patients

                            Details : HMI-115 is a novel prolactin receptor antagonistic antibody. It is under phase 2 clinical development for the treatment of patients with Androgenic Alopecia.

                            Product Name : HMI-115

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 14, 2024

                            Lead Product(s) : HMI-115

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth